For more information, ask your doctor or pharmacist. Please see the RITUXAN full Prescribing Information, including the Medication Guide, for additional. 13 Oct rituximab. PART I: HEALTH PROFESSIONAL INFORMATION. SUMMARY PRODUCT INFORMATION. Route of. Administration. Dosage Form /. Rituxan® SC. rituximab. Product Monograph. RITUXAN SC Product Monograph · Consumer Information. The files in this section are available in

Author: Vojora Goltiktilar
Country: Finland
Language: English (Spanish)
Genre: Art
Published (Last): 19 January 2012
Pages: 23
PDF File Size: 6.73 Mb
ePub File Size: 8.34 Mb
ISBN: 333-2-88756-405-9
Downloads: 96995
Price: Free* [*Free Regsitration Required]
Uploader: Voodooshura

Serious, including fatal, bacterial, fungal, and new or reactivated viral infections can occur during and following the completion of Rituxan-based therapy.

Accessdata Error

You may also report side effects infoormation Genentech at Serious infections can happen during and after treatment with Rituxan and can lead to death. Tell your healthcare provider or get medical help right away if you get any of these symptoms prescriging any time during your treatment with Rituxan: Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Rituxan may cause chest pain, irregular heartbeats, and heart attack. Rituxan prescribing information syndrome may be associated with rituxan prescribing information respiratory failure and death.

In Rituxan-treated RA patients with active disease, subsequent rituxan prescribing information with a biologic DMARD, the majority of which were TNF antagonists, did not appear to increase the rate of serious infection. Severe skin and mouth reactions, Hepatitis B virus presrcibing, Progressive Multifocal Leukoencephalopathy, Serious allergic reactions and other severe reactions.


Genentech does not recommend and does not endorse the content on prrescribing third-party websites. Tell your healthcare provider right away if you have chest pain or irregular heartbeats during treatment with Rituxan.

Your healthcare provider may monitor your heart during and after treatment with Rituxan if you rituxan prescribing information symptoms of heart informationn or have a history of heart problems.

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. There is no known treatment, prevention, or cure for PML.


Tell your healthcare provider right away if you have any symptoms of infection: Rituxan is not recommended for use in patients with severe, active infections.

Reactions were mild or moderate and resolved without any rituxan prescribing information treatment.

Rituximab products can increase your risk of getting infections and can lower the ability of your immune system informaiton fight infections. Talk to your healthcare provider rituxan prescribing information effective birth control.

Click “OK” if you are a healthcare professional. It is not valid for medications the patient infformation for free or that are rituxan prescribing information to be reimbursed by private insurance plans or other health care or pharmaceutical assistance programs that reimburse the patient in whole or in part for the medication.

FDA Internet Application Site (Accessdata) Error

Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites. Rituxan prescribing information your healthcare provider right away if you have new or worsening symptoms rotuxan if anyone close to you notices these symptoms: Severe skin and mouth reactions: Rates of serious infection remain stable in patients receiving irtuxan courses. Rituxan can cause serious side effects that can lead to death, including: Discontinue Rituxan in patients who experience a severe mucocutaneous reaction.


rituxan prescribing information

PML rpescribing result in death or serious disability. PML can result in death or severe disability. Hepatitis B reactivation may cause serious rituxan prescribing information problems, including liver failure and death. Rituximab product administration should be interrupted immediately and aggressive symptomatic treatment initiated During RITUXAN HYCELA administration, the injection should be interrupted immediately when observing signs of a severe reaction and aggressive symptomatic treatment should be initiated.

Infusion reactions are very common side effects of Rituxan treatment. Closely monitor the following patients: By selecting this link, you will rituxan prescribing information leaving Rituxan.

Rituxan administration can result in serious, including fatal infusion reactions. Rituxan can cause serious side effects that can lead to death, including: In the experience with Rituxan in RA patients, the rate of serious infection was 4.

Other side effects include: More frequent rituxan prescribing information respiratory tract infections.